Patient specific dosing: a fitter model in dialysis patient with

Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium tuberculosis and is a major cause of morbidity and mortality in developing countries. There are no randomized controlled trials that provide evidence to guide TB treatment in renal failure.
Case report: A 69 year old male patient was admitted in a secondary care hospital on 6th October and discharged on 21st October having 52.2kg body weight. He presented with hiccups and unresponsiveness. He had a past medical history of Diabetes mellitus (25 years), Hypertension (23 years) and Pulmonary Tuberculosis (2013). At present he also presented with complaints of End stage renal disease and pleural effusion tuberculosis (4 months) and was on medicines such as Tab. AKT4 (Isoniazid, Rifampin, Pyrazinamide and Ethambutol), Tab. Arkamin (clonidine), Tab. GTN (Nitroglycerin), Tab. Shelcal (Calcium carbonate and vitamin D3), Tab. Pyridexin (vitamin B6), Tab. Nicardia (Nifedipine). The tuberculosis medicines were discontinued without informing the doctor few weeks ago and restarted prior to this admission. The patient was on haemodialysis twice weekly due to End- Stage Renal Disease (ESRD). The critical evaluation of patient by clinical pharmacist the patient recovered and the therapy was modified according to patient condition and the errors were rectified. Conclusion: This case report illustrates the need of thorough monitoring by Clinical Pharmacist in the patient oriented management and pharmaceutical care that should be provided for vulnerable population